1UK Prospective Diabetes Study(UKPDS)Group.Intensiveblood-glucose control with sulphonylureas or insulin compared withconventional treatment and risk of complications in patients with type 2 diabetes(UKPDS33).Lancet,1998,352(9131):837-853
2Klagsbrun M.Vascular endothelial growth factor and itsreceptors.Cytokine GrowthFactor Rev,1996,7(3):259-270
3Tolentino MJ.Intravitreous injections of vascular endothelial growth factor produceretinal ischemia and microagiopthy in an adultprimate.Ophthalmology,1996,103(11):1820-1828
4Maisonpierre PC.Angiopoietin-2 a natural antagonist for Tie2 that disrupts in vivoangiogenesis.Science,1997,277(5322):55-60
5Mandriota SJ.Regulation of angiopoietin-2 mRNA leves in bovine microvascularendothelial cells by cytokines and hypoxia.Circ Res,1998,83(8):852-859
6Ishii H.Amelioration of vascular dysfunctions in diabetic rats by an oral PKC βinhibitor.Science,1996,272(5262):728-731
7Murata T.The relationship between accumulaiton of advanced glycation end productsand expression of vascular endothelial growth factor in human diabeticretinas.Diabetologia,1997,40(7):764-769
